Table 2.

Baseline risk factors for ILD progression following treatment with RTX

Characteristics	RA-ILD patients who had lung progression (n = 14)	RA-ILD patients with stable/improved lung (n = 30)	P-value
Age, median (IQR), years	70 (61–73)	63 (59–68)	0.302
Male, n (%)	8 (57)	8 (27)	0.091
ILD disease duration, median (IQR), years	5.5 (3–9)	6.0 (3–7)	0.678
Previous history of lung progression, n (%)	11 (79)	6 (20)	0.001*
Ever smoking, n (%)	8 (57)	15 (50)	0.752
Concomitant DMARDs, n (%)	7 (54)	19 (66)	0.322
Corticosteroid dose, median (IQR), mg	7.5 (1.9–10)	0 (0–5)	0.054
Radiographic pattern of UIP, n (%)	9 (64)	8 (29)	0.045*
CRP at first RTX infusion, median (IQR)	24 (12–35)	12 (1–41)	0.348
DLCO at first RTX infusion, median (IQR), % predicted	42 (41–49)	59 (54–64)	0.031*

Mann–Whitney U and Fisher’s exact tests were used appropriately to test for differences between groups. *P < 0.05, significant results.